Kishimoto T, Fujimoto N, Ebara T, et al. - Researchers investigated serum levels of C-C motif chemokine ligand 2 (CCL2) in mesothelioma patients, using ELISA, in this study performed on 50 malignant pleural mesothelioma (MPM) patients and 356 people who were likely exposed to asbestos but did not develop disease symptoms and 41 healthy volunteers without a history of exposure to asbestos. They found significantly elevated serum levels of CCL2 in patients with advanced MPM. The results were compatible with the premise suggesting a crucial role of CCL2/CCR2 axis and myeloid-derived cells in MPM and disease progression. Treatments targeting CCL2/CCR2 and tumor resident myeloid cells are being developed, and clinical trials utilizing these therapies as part of the treatment regimen are being pursued.